托伐普坦治疗与常染色体显性多囊肾病患者矿物质代谢参数改变及骨密度增加相关
在伯尔尼ADPKD登记的前瞻性观察队列中,189例参与者(122例未用托伐普坦、67例后续使用)分析显示,托伐普坦治疗与股骨颈骨密度增加(β=0.092,95%CI 0.001-0.183,P=0.047)及血浆镁、碳酸氢盐、尿pH升高、甲状旁腺激素、1,25(OH)D3、尿镁排泄分数降低相关。
要点
- 托伐普坦治疗与股骨颈骨密度增加相关(β=0.092,95%CI 0.001-0.183,P=0.047)。
- 托伐普坦治疗与血浆镁、碳酸氢盐和尿pH升高相关。
- 托伐普坦治疗与甲状旁腺激素、1,25(OH)D3及尿镁排泄分数降低相关。
核心结论
- 慢性托伐普坦治疗与ADPKD患者股骨骨密度增加以及矿物质代谢和酸碱参数显著改变相关。
研究设计与样本
- 基于伯尔尼ADPKD登记的前瞻性观察队列分析,共纳入189例参与者,其中122例未接受托伐普坦治疗,67例后续接受托伐普坦治疗。
- 基线及此后每12个月测量矿物质代谢参数,基线及3年后通过双能X线吸收法测定骨密度,采用多变量混合效应回归模型评估托伐普坦治疗相关的参数变化。
主要发现
- 托伐普坦治疗与股骨颈骨密度增加相关(β=0.092,95%CI 0.001-0.183,P=0.047)。
- 托伐普坦治疗与较高的血浆镁相关(β=0.019,95%CI 0.001-0.037,P=0.037)。
- 托伐普坦治疗与较高的碳酸氢盐相关(β=0.972,95%CI 0.242-1.702,P=0.009)。
- 托伐普坦治疗与较高的尿pH相关(β=0.214,95%CI 0.056-0.372,P=0.008)。
- 托伐普坦治疗与较低的甲状旁腺激素相关(β=-0.191,95%CI -0.328至-0.053,P=0.006),与较低的1,25(OH)D3相关(β=-0.126,95%CI -0.235至-0.164,P=0.024),与较低的尿镁排泄分数相关(β=-0.473,95%CI -0.622至-0.324,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of tolvaptan treatment on mineral metabolism and bone mineral density (BMD) is unknown. METHODS: We conducted an analysis in the Bern ADPKD Registry, a prospective observational cohort study. Mineral metabolism parameters were measured at baseline and every 12 months thereafter. BMD was determined by dual-energy X-ray absorptiometry at baseline and after 3 years. Multivariable mixed-effects regression models were applied to assess changes in mineral metabolism parameters and BMD associated with tolvaptan treatment. RESULTS: A total of 189 participants (122 without and 67 with subsequent tolvaptan treatment) were included in the analysis. During follow-up, tolvaptan treatment was associated with increased BMD at the femoral neck {β = 0.092 [95% confidence interval (CI) 0.001-0.183], P = .047}. In addition, tolvaptan treatment was associated with higher plasma magnesium [β = 0.019 (95% CI 0.001-0.037), P = .037], bicarbonate [β = 0.972 (95% CI 0.242-1.702), P = .009] and urine pH [β = 0.214 (95% CI 0.056-0.372), P = .008] and lower parathyroid hormone [β = -0.191 (95% CI -0.328 to -0.053), P = .006], 1,25(OH)D3 [β = -0.126 (95% CI -0.235 to -0.164), P = .024] and fractional urinary magnesium excretion [β = -0.473 (95% CI -0.622 to -0.324), P < .001]. CONCLUSIONS: Chronic tolvaptan treatment is associated with increased femoral BMD and significant changes in both mineral metabolism and acid-base parameters in ADPKD patients.
引用
- Bargagli M, Vetsch A, Anderegg MA, et al. Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrol Dial Transplant. 2023. PMID: 36309473. doi:10.1093/ndt/gfac298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。